Per protocol stopping rule was met for a separate trial for a different disease state and different experimental therapy that utilized a similar technology.
Summary
The goal of this clinical trial is to learn about the safety of CAP-003 gene therapy in adults with GBA1 associated Parkinson's Disease. It will also provide information about whether CAP-003 demonstrates efficacy in these adults.
Participants will have a single intravenous infusion of CAP-003 and visit the clinic regularly for 2 years for checkups and tests.
Protocol Amendment History
8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-06-02; most recent amendment 2026-06-18.
Status change: Suspended → Withdrawn2026-06-18
Status change: Recruiting → Suspended2025-09-23
Status change: Not Yet Recruiting → Recruiting2025-08-14